Last 41 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -11.98 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 25.85 | — | — | 116.14 | 52.11 | 18.92 | 13.14 | 5.02 | 4.85 | 4.26 | 3.56 | 5.43 | 3.01 | 2.18 | 2.19 | 1.80 | 1.77 | 3.45 | 2.55 | 2.27 | 2.86 |
| — | — | — | +2212.5% | +973.6% | +343.8% | +268.6% | -7.5% | +61.1% | +95.8% | +62.8% | +201.0% | +70.5% | -36.8% | -14.3% | -20.4% | -38.3% | -4.2% | -77.2% | -49.8% | -64.4% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -163.8% | — | -387.1% | -68.6% | -46.9% | -54.3% | -69.1% | -36.6% | -27.6% | -18.3% | -15.3% | -15.8% | -16.2% | -18.1% | -12.5% | -9.3% | -13.1% | -22.5% | -17.4% | -12.2% | -9.4% |
| — | — | -460.3% | -87.5% | -69.6% | -197.5% | -352.0% | -131.5% | -70.5% | -0.7% | -22.2% | -70.1% | -24.0% | +19.5% | +28.0% | +23.7% | -38.5% | -89.7% | +61.5% | -2.3% | +52.9% | |
| ROA | -49.8% | -9.4% | -12.7% | -12.1% | -10.8% | -13.3% | -22.5% | -16.0% | -14.1% | -10.5% | -9.9% | -11.4% | -11.3% | -12.4% | -9.2% | -7.0% | -9.6% | -15.8% | -13.1% | -9.6% | -7.6% |
| — | +29.0% | +43.5% | +24.5% | +23.5% | -26.1% | -128.4% | -40.2% | -25.2% | +15.3% | -7.7% | -62.5% | -17.6% | +21.4% | +30.0% | +26.7% | -26.5% | -76.8% | +63.1% | +15.5% | +58.5% | |
| ROIC | -80.4% | -10.9% | -14.9% | -32.4% | -15.0% | -14.0% | -24.8% | -15.1% | -12.8% | -9.5% | -9.5% | -11.8% | -11.8% | -13.0% | -9.4% | -7.0% | -12.0% | -567.6% | — | — | — |
| — | +21.8% | +39.7% | -114.9% | -16.5% | -47.7% | -160.7% | -28.1% | -8.8% | +27.1% | -1.0% | -68.7% | +1.4% | +97.7% | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.94 | — | — | 3.65 | 1.94 | 2.74 | 2.24 | 1.14 | 0.85 | 0.65 | 0.55 | 0.28 | 0.27 | 0.40 | 0.33 | 0.29 | 0.26 | 0.35 | 0.29 | 0.24 | 0.22 |
| — | — | — | +220.8% | +129.3% | +321.9% | +310.1% | +301.6% | +216.2% | +63.2% | +64.8% | -3.0% | +1.7% | +13.1% | +16.2% | +19.7% | +21.6% | +77.9% | -46.4% | +3926.1% | +865.8% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 10.55 | 14.62 | 8.93 | 12.31 | 10.55 | 12.26 | 4.58 | 6.61 | 7.71 | 10.36 | 14.95 | 11.23 | 13.43 | 11.15 | 21.58 | 28.26 | 25.45 | 9.74 | 17.34 | 22.37 | 34.06 |
| — | +19.3% | +94.8% | +86.3% | +36.8% | +18.4% | -69.3% | -41.1% | -42.6% | -7.1% | -30.7% | -60.3% | -47.2% | +14.5% | +24.4% | +26.3% | -25.3% | -69.9% | -36.9% | -26.7% | +231.8% | |
| Quick Ratio | 10.55 | 14.59 | 8.93 | 12.31 | 10.55 | 12.26 | 4.58 | 6.61 | 7.71 | 10.36 | 14.95 | 11.23 | 13.43 | 11.15 | 21.58 | 28.26 | 25.45 | 9.74 | 17.34 | 22.37 | 34.06 |
| — | +19.0% | +94.8% | +86.3% | +36.8% | +18.4% | -69.3% | -41.1% | -42.6% | -7.1% | -30.7% | -60.3% | -47.2% | +14.5% | +24.4% | +26.3% | -25.3% | -69.9% | -36.9% | -26.7% | +231.8% | |
| Interest Coverage | -9.32 | -26.25 | -10.08 | -7.68 | -7.27 | -2.26 | -13.13 | -10.62 | -10.19 | -7.91 | -9.49 | -14.43 | -12.49 | -12.41 | -10.09 | -8.61 | -17.17 | -19.26 | -20.87 | -17.24 | -14.42 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 41 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CELC stock.
Celcuity Inc.'s current P/E is -12.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Celcuity Inc.'s business trajectory between earnings reports.